User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.00 -1.56% 886.00 870.00 890.00 895.00 875.00 895.00 74,149 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 659

Maxcyte Share Discussion Threads

Showing 626 to 650 of 725 messages
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
14/4/2021
09:20
Assagai, Based on last year I thought Tuesday 20/4/2021. CNBC saying, Elsewhere, Wood said the genomics space is also set to hit escape velocity. “DNA sequencing is going to introduce science into healthcare decision making for the first time,” said Wood. “We can honestly say that until now more than half of all healthcare decisions were in some part made through guesses or experiences. Now we’re going to have the data.” ARK’s Genomics ETF has big bets on Exact Sciences, which makes up nearly 5% of the ETF, and Invitae. CRISPR Therapeutics is another major holding in the ETF. “We’re going to be able to cure diseases that we never thought it would be possible to cure, including cancer,” said Wood.
bamboo2
14/4/2021
09:18
Results within 2 weeks? Optimistic..
assagai
14/4/2021
09:06
Added a few more. Spread just 1p at present, 844-845 Odd, just noticed I can buy at 844 and sell at 845!
bamboo2
14/4/2021
08:47
Last trade of 591 was a buy
montynj
07/4/2021
15:05
Bought back a few yesterday and today at 869 and 869.9
bamboo2
23/3/2021
18:56
Nice find by Sahara 'Interesting study by Glaxo comparing Maxcyte $MXCT to the distant #2 in electroporation Lonza First time I've seen the difference quantified in a head-to-head comparison.' hTTps://twitter.com/saharainvesting/status/1374432147394629644?s=19
homebrewruss
23/3/2021
09:08
That could be material to MXCT. Don't they get a revenue share from that?
donald pond
22/3/2021
17:07
MaxCyte, Inc. @MaxCyte_info Congratulations to our partner, @SangamoTx, on the Orphan Designation for BIVV003 for the treatment of #sicklecelldisease: http://ow.ly/ytDJ50E5dJJ via @GENbio. @sanofi @EMA_News #celltherapy #SCD
someuwin
15/3/2021
10:05
This is a 'picks and shovels' business to a high risk high reward industry, as such it benefits either way and doesn't carry the risk. It also benefits if someone strikes gold, in that in addition, it earns royalties from successful outcomes. One other positive is - it earns very high margin on equipment sales as well as the consumables. Usually, consumable businesses earn low margin on equipment sales and make their money on the consumable, this outfit is attractive.
owenski
15/3/2021
10:00
Valuation is impossible at the moment - could argue its worth billions or £7 a share depending on the view one wants to take or market conditions perhaps. Some of the best investors in America wanted to got involved at £7 (this counts as the most recent independent valuation by professionals) and 2 brokers think it's worth £12 +. (But broker targets don't mean a lot to me other than perhaps potential direction of travel). It'll be worth billions if a drug makes it to market and so far most advanced is Crispr Sickle Cell at 70% COS. But as ever nothing is certain until it happens. One pays up, holds or sells accordingly. Under researched / unbalanced posting is just trolling and deserves to be ignored.
nimbo1
15/3/2021
07:58
Don't forget pre commercial milestones so it makes money as the drugs pass through clinical trials. Repeat sales of consumables and cell therapy drugs have already been approved it's not like this is a completely new area awaiting the first approval. Expecting more partnerships as well:- As of February 2020, there are nine cell or gene therapy products approved in the U.S. – treating cancer, eye diseases and rare hereditary diseases. Biopharmaceutical researchers are using these new technologies and pursuing innovative treatments in clinical trials today. "CELL AND GENE THERAPY - PhRMA Org". You can Google it to see the pdf document.
hj996
15/3/2021
07:48
The business model has parallels with that of ARM back in the mid-1990s. But of course the underlying therapeutics may not work in which case it is worth zero.
trickydicky1
14/3/2021
23:37
How much should the world leader in it chosen cell therapy field be worth? Not a leader but the leader. Why are US specialist funds rushing to buy up as much of the sells as they can? There were trades in the millions snapped up over £10. The question is not if they will struggle to sell but where will those companies in need of these products go? They will come knocking on MaxCyte's door. Why would they want to use an inferior competitors product when they are spending hundreds of millions on research and trials and MaxCyte's products will add extra value and efficiency to their drugs etc.? Only facts and solid opinions presented in the YouTube video. It's actually a derisked way into the cell therapy field. Others take the risk and pay you for it as well. MaxCyte is therefore like a fund - stakes through the licensing, royalty agreements etc. in pretty much all the leading cell therapy companies and others. If one fails to succeed one or more of the others most likely will. A unique business model where else will you find this? I recall the CEO saying as much in his latest talk that there is no other such business model.
hj996
14/3/2021
23:31
Zub Everything is good for me at the right value and right price
stockready
14/3/2021
21:11
Thanks stockready. Sounds like its not for you this one, plenty more to chose from. GL
zubes
14/3/2021
20:41
Assagai Thanks mate, yes managed to watch the youttube the right one this time The CEO seems a camera shy Sarah had to tell him to turn on the camera. It was an interesting presentation which he draw a very rosy pictures but fall short of explaining how many of these devices he is going to sell and how many he sold so far? These are the key questions people will ask I don't care about how many sold in the past i care about hos projection to the future of how many he will sell!! Which none of that in the presentation Also he mention Astra Zenica without mentioning the future relation andnif they need more, also lots of words such as ... likely, predicted, possible etc which is not really reassuring for the investors If all the picture are so rosy why the share price is not £20 or evem more... surely some hesitation on the value and delivery what he says doesn't mean it will happen. Pharma companies are so picky with their choice and need a book like thesis to convince them to buy anything. This is not as easy as he made it at all. Overal nice solid idea but delivery to the market is far harder than portraited here I am not saying is bad but i say be careful with how this is valued GLA IMHO
stockready
14/3/2021
16:12
Https://www.youtube.com/watch?v=UMzC44ahzVs
owenski
14/3/2021
15:42
Post 615...Stockready
assagai
14/3/2021
15:27
Stock ready may not be ready to smile today
eaglebeagle
14/3/2021
15:00
Which youtube? Are you referring to that stupid guy with sun glasses (funky finance) talking all loads of BS? REALLY!? Does any wise investors invest a penny based on those loads of utter BS that guy is throwing out his pram? No Unless i missed something or you mean a different youtube link
stockready
14/3/2021
14:53
Stocktready, perhaps we should start with your first two pronouncements, both of which are fundamentally incorrect. The best thing to do is open the YouTube link above. Listen to that and then you may very well want to get onboard! Oh and I'll have a small wager that we will close on Friday above last Friday's close.
assagai
14/3/2021
13:14
Can someone tell me why this rocketed up tbis much while their business is nothing new and other companies are doing this in larger scales? Does the recent corrections will continue? Thanks
stockready
12/3/2021
16:02
This stock is seen by the UK market as being expensive based on current revenues. As soon as it lists on Nasdaq, the US market will see it as being ludicrously cheap based on future earnings.
someuwin
12/3/2021
13:19
Apologies if not relevent but I hadn't noticed before that Maxcyte had a US OTC listing OTCMKTS: MAXC Anyway, it is good to note they have a Nasdaq page in preparation for a future listing.... hTTps://www.nasdaq.com/market-activity/stocks/maxc
pob69
12/3/2021
12:57
Thanks. The blue sky dcf valuation they give is £24 and £12.40 the base case.
nimbo1
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 14:49:02